Patents by Inventor Stéphanie MONLEZUN

Stéphanie MONLEZUN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230226076
    Abstract: The present invention generally relates to a specific pregnenolone derivative for its use for the treatment of a Cannabinoids-Related Disorder. More particularly, the invention relates to a compound of Formula (I) for its use in the treatment of a Cannabinoids-Related Disorder. Indeed, the compound of the invention is in vivo very potent in inhibiting the effects of THC, and is able to inhibit both unconditioned and conditioned effects of THC including THC self-administration and reinstatement in THC seeking in non-human primates.
    Type: Application
    Filed: September 15, 2022
    Publication date: July 20, 2023
    Inventors: Pier Vincenzo PIAZZA, Sandy FABRE, Mathilde METNA, Stéphanie MONLEZUN, Arnau BUSQUET-GARCIA, Daniela COTA, Giovanni MARSICANO, Jean-Michel REVEST, Monique VALLEE
  • Patent number: 11484537
    Abstract: The present invention generally relates to a specific pregnenolone derivative for its use for the treatment of a Cannabinoids-Related Disorder. More particularly, the invention relates to a compound of Formula (I) for its use in the treatment of a Cannabinoids-Related Disorder. Indeed, the compound of the invention is in vivo very potent in inhibiting the effects of THC, and is able to inhibit both unconditioned and conditioned effects of THC including THC self-administration and reinstatement in THC seeking in non-human primates.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: November 1, 2022
    Assignees: AELIS FARMA, INSERM (Institut National de la Santé et de la Recherche Médicale), UNIVERSITE DE BORDEAUX
    Inventors: Pier Vincenzo Piazza, Sandy Fabre, Mathilde Metna, Stéphanie Monlezun, Arnau Busquet-Garcia, Daniela Cota, Giovanni Marsicano, Jean-Michel Revest, Monique Vallée
  • Publication number: 20220017562
    Abstract: The present invention generally relates to a specific pregnenolone derivative for its use for the treatment of a cognitive disorders. More particularly, the invention relates to a compound of Formula (I) for its use in the treatment of cognitive disorders. Indeed, the compound of the invention is in vivo very potent in correcting the cognitive impairments observed in cognitive disorders.
    Type: Application
    Filed: December 18, 2019
    Publication date: January 20, 2022
    Inventors: Pier Vincenzo PIAZZA, Sandy FABRE, Stéphanie MONLEZUN, Mathilde METNA, Monique VALLEE, Jean-Michel REVEST, Daniela COTA, Giovanni MARSICANO, Aline MARIGHETTO, Andrés OZAITA, Rafael MALDONADO
  • Publication number: 20210030768
    Abstract: The present invention generally relates to a specific pregnenolone derivative for its use for the treatment of a Cannabinoids-Related Disorder. More particularly, the invention relates to a compound of Formula (I) for its use in the treatment of a Cannabinoids-Related Disorder. Indeed, the compound of the invention is in vivo very potent in inhibiting the effects of THC, and is able to inhibit both unconditioned and conditioned effects of THC including THC self-administration and reinstatement in THC seeking in non-human primates.
    Type: Application
    Filed: February 20, 2019
    Publication date: February 4, 2021
    Inventors: Pier Vincenzo PIAZZA, Sandy FABRE, Mathilde METNA, Stephanie MONLEZUN, Arnau BUSQUET-GARCIA, Daniela COTA, Giovanni MARSICANO, Jean-Michel REVEST, Monique VALLEE